Objective: The aim: To determine the dynamics of galectin-3 in the formation of the patient's clinical profile and the impact on structural cardiac and vascular remodeling in patients with myocardial infarction after reperfusion therapy.
Patients And Methods: Materials and methods: 140 patients with class II A CHF syndrome according to Vasilenko-Strazhesko FC II-III (NYHA), which occurred in patients with MI, and 22 patients with MI without signs of CHF were examined.
Results: Results: The average serum galectin-3 level of the studied patients was analyzed.